A summit on the rapidly growing LNP-based nanomedicines market
Lipid Nanoparticles (LNP), the chosen delivery method for mRNA therapies such as mRNA based COVID-19 vaccines, represent a new pharmaceutical revolution that KNAUER are proud to be part of - Since 2020 we have been supplying some of the World's largest mRNA-based vaccine producers with our IJM NanoProducer Units for the large-scale production of LNPs.
The global nanopharmaceutical market is growing rapidly and is expected to reach a value of 82.7 billion USD over the next five years. The growth of mRNA based therapies, as well as protein-based nanomedicines, means LNPs are a hot topic. The first ever LNP Formulation & Process Development Summit brings together drug developers and their industrial partners to share ideas, solutions and see the latest in LNP technology.
KNAUER is excited to be there! Our IJM NanoProducer Units are being used for LNP production the world over from pilot to manufacturing scale.
In addition, we have a new development to share - our IJM NanoScaler. An LNP system that is made with research and development in mind.
Two of KNAUER's brightest - our CEO, Carsten Losch, and head of Purification and Custom Solutions, Anja Roden, will be at the Summit to talk everything LNP with you!
Registration is possible using the link below.
